The focus of the discussion was on the preventive aspects of the Affordable Care Act, which includes genetic testing for cancer risk and prevention. As part of Pathway Genomics’ commitment to advancing health care, it plans to offer its cancer panel to physicians at an affordable cost.

This month, Pathway Genomics’ founder and CEO, Jim Plante, attended an exclusive dinner event with President Barack Obama. The focus of the discussion was on the preventive aspects of the Affordable Care Act, which includes genetic testing for cancer risk and prevention. As part of Pathway Genomics’ commitment to advancing health care, it plans to offer its cancer panel to physicians at an affordable cost.

“By offering a comprehensive cancer panel, we are doing our part in helping to reduce the number of cancer victims across the nation – and around the world,” said Plante.

“By offering a comprehensive cancer panel, we are doing our part in helping to reduce the number of cancer victims across the nation – and around the world,” said Plante. “The new Affordable Care Act will make these types of genetic tests even more accessible to a wider patient base, benefiting more people, which is a vital component of our goal and responsibility as a clinical laboratory.” The Centers for Disease Control and Prevention estimates breast and ovarian cancer cases in the U.S. at more than 200,000 cases per year – and more than 50,000 deaths per year are caused by these two cancers combined.

Pathway Genomics’ Hereditary Cancer DNA InsightSM test will utilize next-generation sequencing (NGS) technology and analyze genes related to a selection of hereditary cancers including breast, ovarian, colorectal and others.

Pathway Genomics’ cancer panel will utilize next-generation sequencing (NGS) technology and analyze genes related to a selection of hereditary cancers including breast, ovarian, colorectal and others.

Read about Pathway Genomics’ cancer panel and its ongoing involvement in joining the fight against cancer…

Comments are closed.